United Therapeutics Co. (NASDAQ:UTHR) Receives $308.78 Consensus PT from Analysts

Shares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have received an average rating of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $308.78.

A number of equities research analysts have weighed in on UTHR shares. The Goldman Sachs Group boosted their price objective on United Therapeutics from $218.00 to $240.00 and gave the company a "neutral" rating in a research note on Friday, May 3rd. Leerink Partnrs restated an "outperform" rating on shares of United Therapeutics in a research note on Monday, February 5th. Oppenheimer increased their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an "outperform" rating in a research note on Thursday, May 2nd. Wells Fargo & Company boosted their price target on United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a research report on Thursday, March 7th. Finally, StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Christopher Patusky sold 1,310 shares of the company's stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $264.35, for a total transaction of $346,298.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business's stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $265.48, for a total value of $955,728.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $34,512.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher Patusky sold 1,310 shares of United Therapeutics stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $264.35, for a total value of $346,298.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 150,140 shares of company stock valued at $36,051,162. 12.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the stock. Rise Advisors LLC purchased a new position in shares of United Therapeutics during the 1st quarter worth $32,000. GAMMA Investing LLC acquired a new stake in United Therapeutics in the 4th quarter worth about $43,000. Benjamin F. Edwards & Company Inc. grew its holdings in United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company's stock valued at $69,000 after buying an additional 117 shares during the period. C M Bidwell & Associates Ltd. acquired a new position in shares of United Therapeutics during the 3rd quarter valued at about $91,000. Finally, Janiczek Wealth Management LLC lifted its holdings in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company's stock worth $111,000 after acquiring an additional 84 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Up 0.7 %

NASDAQ:UTHR traded up $2.04 during midday trading on Friday, reaching $274.26. The company had a trading volume of 329,299 shares, compared to its average volume of 578,775. The firm has a market capitalization of $12.17 billion, a price-to-earnings ratio of 12.97 and a beta of 0.54. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The stock's fifty day simple moving average is $244.01 and its 200-day simple moving average is $232.40. United Therapeutics has a 12-month low of $204.44 and a 12-month high of $275.00.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating analysts' consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to analysts' expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics's quarterly revenue was up 33.7% compared to the same quarter last year. During the same period in the previous year, the company earned $4.86 earnings per share. On average, sell-side analysts anticipate that United Therapeutics will post 24.2 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.